摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Phenyl-2.6-dichlor-3-methyl-anilin | 1618-57-1

中文名称
——
中文别名
——
英文名称
N-Phenyl-2.6-dichlor-3-methyl-anilin
英文别名
N-Phenyl-2.6-dichlor-m-toluidin;(2',6'-dichloro-3'-methyl)diphenylamine;2-[(2,6-dichloro-3-methylphenyl)amino]-benzene;2,6-dichloro-3-methyl-N-phenylaniline
N-Phenyl-2.6-dichlor-3-methyl-anilin化学式
CAS
1618-57-1
化学式
C13H11Cl2N
mdl
——
分子量
252.143
InChiKey
SLPAPGNFCSVQKP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    76-78 °C
  • 沸点:
    115-120 °C(Press: 0.001 Torr)
  • 密度:
    1.288±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.5
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and quantitative structure-activity relationships of diclofenac analogs
    摘要:
    The synthesis of a series of 2-anilinophenylacetic acids, close analogues of diclofenac, is described. These compounds were tested in two models used for evaluating the activity of nonsteroidal antiinflammatory drugs (NSAID's), inhibition of cyclooxygenase enzyme activity in vitro, and adjuvant-induced arthritis (AdA) in rats. Statistically significant correlations were found between the inhibitory activities of the compounds in these two models, indicating that cyclooxygenase inhibition seems to be the underlying mechanism for the antiinflammatory activity of these compounds. Quantitative structure-activity relationship (QSAR) analysis revealed that the crucial parameters for activity in both models were the lipophilicity and the angle of twist between the two phenyl rings. Optimal activities were associated with halogen or alkyl substituents in both ortho positions of the anilino ring. Compounds with OH groups in addition to two ortho substituents or compounds with only one or no ortho substituents were less active.
    DOI:
    10.1021/jm00171a008
  • 作为产物:
    描述:
    劳森试剂2-[(2,6-dichloro-3-methylphenyl)amino]-benzamide氮气正己烷乙酸乙酯 作用下, 以 四氢呋喃 为溶剂, 反应 74.0h, 以ethyl acetate (gradient of 6:1 to 3:1), providing 1.71 g (57%) of a pale yellow solid的产率得到N-Phenyl-2.6-dichlor-3-methyl-anilin
    参考文献:
    名称:
    Fenamate 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as antiinflammatory
    摘要:
    本发明涉及一种新型化合物,其为1,3,4-噻二唑和1,3,4-噁二唑,以及其药学上可接受的酸加合物或碱盐,具有抑制单独或联合5-脂氧合酶和环氧合酶的活性,以及其制药组合物或使用方法。
    公开号:
    US05462952A1
点击查看最新优质反应信息

文献信息

  • Fenamic acid hydroxamate derivatives having cyclooxygenase and
    申请人:Warner-Lambert Company
    公开号:US05155110A1
    公开(公告)日:1992-10-13
    The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods for treating these conditions in mammals, including humans suffering therefor.
    本发明是关于选择的具有5-脂氧合酶和环氧合酶抑制作用的非那酸的新颖羟肟酸衍生物,以及用于治疗受到这种抑制有利影响的疾病的药物组合物和治疗这些疾病的方法,包括患有这些疾病的哺乳动物,包括人类。
  • Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
    申请人:Exocell, Inc.
    公开号:US06355680B1
    公开(公告)日:2002-03-12
    The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.
    本发明涉及抑制白蛋白非酶促糖基化的组合物,以及利用抑制白蛋白糖基化的化合物治疗糖基化相关病理的方法。
  • Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
    申请人:WARNER-LAMBERT COMPANY
    公开号:EP0316630A1
    公开(公告)日:1989-05-24
    The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods for treating these conditions in mammals, including humans suffering therefor.
    本发明是具有 5-脂氧合酶和环氧合酶抑制特性的新型精选非那西酸羟肟酸衍生物、用于治疗受其抑制作用有利影响的病症的药物组合物,以及治疗哺乳动物(包括受其影响的人类)的这些病症的方法。
  • ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES
    申请人:EXOCELL, INC.
    公开号:EP1242069A2
    公开(公告)日:2002-09-25
  • METHODS OF SCREENING USING AMPHIBIANS
    申请人:Brändli, André W.
    公开号:EP2409149B1
    公开(公告)日:2015-11-11
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐